130 related articles for article (PubMed ID: 33500319)
41. Aberrant promoter methylation of PPP1R3C and EFHD1 in plasma of colorectal cancer patients.
Takane K; Midorikawa Y; Yagi K; Sakai A; Aburatani H; Takayama T; Kaneda A
Cancer Med; 2014 Oct; 3(5):1235-45. PubMed ID: 24861485
[TBL] [Abstract][Full Text] [Related]
42. RAS mutation analysis in circulating tumor DNA from patients with metastatic colorectal cancer: the AGEO RASANC prospective multicenter study.
Bachet JB; Bouché O; Taieb J; Dubreuil O; Garcia ML; Meurisse A; Normand C; Gornet JM; Artru P; Louafi S; Bonnetain F; Thirot-Bidault A; Baumgaertner I; Coriat R; Tougeron D; Lecomte T; Mary F; Aparicio T; Marthey L; Taly V; Blons H; Vernerey D; Laurent-Puig P
Ann Oncol; 2018 May; 29(5):1211-1219. PubMed ID: 29438522
[TBL] [Abstract][Full Text] [Related]
43. Circulating tumour DNA as a biomarker in resectable and irresectable stage IV colorectal cancer; a systematic review and meta-analysis.
Jones RP; Pugh SA; Graham J; Primrose JN; Barriuso J
Eur J Cancer; 2021 Feb; 144():368-381. PubMed ID: 33422803
[TBL] [Abstract][Full Text] [Related]
44. BMP3 promoter hypermethylation in plasma-derived cell-free DNA in colorectal cancer patients.
Rokni P; Shariatpanahi AM; Sakhinia E; Kerachian MA
Genes Genomics; 2018 Apr; 40(4):423-428. PubMed ID: 29892846
[TBL] [Abstract][Full Text] [Related]
45. Hypermethylation and decreased expression of TMEM240 are potential early-onset biomarkers for colorectal cancer detection, poor prognosis, and early recurrence prediction.
Chang SC; Liew PL; Ansar M; Lin SY; Wang SC; Hung CS; Chen JY; Jain S; Lin RK
Clin Epigenetics; 2020 May; 12(1):67. PubMed ID: 32398064
[TBL] [Abstract][Full Text] [Related]
46. Hypermethylated DNA, a circulating biomarker for colorectal cancer detection.
Rasmussen SL; Krarup HB; Sunesen KG; Johansen MB; Stender MT; Pedersen IS; Madsen PH; Thorlacius-Ussing O
PLoS One; 2017; 12(7):e0180809. PubMed ID: 28700744
[TBL] [Abstract][Full Text] [Related]
47. Performance of epigenetic markers SEPT9 and ALX4 in plasma for detection of colorectal precancerous lesions.
Tänzer M; Balluff B; Distler J; Hale K; Leodolter A; Röcken C; Molnar B; Schmid R; Lofton-Day C; Schuster T; Ebert MP
PLoS One; 2010 Feb; 5(2):e9061. PubMed ID: 20140221
[TBL] [Abstract][Full Text] [Related]
48. Clinicopathologic Characteristics of HER2-positive Metastatic Colorectal Cancer and Detection of HER2 in Plasma Circulating Tumor DNA.
Wei Q; Zhang Y; Gao J; Li J; Li J; Li Y; Zhou J; Lu M; Gong J; Zhang X; Shen L; Sun Y; Chang L; Wang X
Clin Colorectal Cancer; 2019 Sep; 18(3):175-182. PubMed ID: 31227437
[TBL] [Abstract][Full Text] [Related]
49. Circulating cell-free DNA in plasma of colorectal cancer patients - A potential biomarker for tumor burden.
Bhangu JS; Taghizadeh H; Braunschmid T; Bachleitner-Hofmann T; Mannhalter C
Surg Oncol; 2017 Dec; 26(4):395-401. PubMed ID: 29113658
[TBL] [Abstract][Full Text] [Related]
50. From discovery to the clinic: the novel DNA methylation biomarker (m)SEPT9 for the detection of colorectal cancer in blood.
Payne SR
Epigenomics; 2010 Aug; 2(4):575-85. PubMed ID: 22121975
[TBL] [Abstract][Full Text] [Related]
51. Circulating methylated SEPT9 DNA in plasma is a biomarker for colorectal cancer.
deVos T; Tetzner R; Model F; Weiss G; Schuster M; Distler J; Steiger KV; Grützmann R; Pilarsky C; Habermann JK; Fleshner PR; Oubre BM; Day R; Sledziewski AZ; Lofton-Day C
Clin Chem; 2009 Jul; 55(7):1337-46. PubMed ID: 19406918
[TBL] [Abstract][Full Text] [Related]
52. Enhanced Performance of DNA Methylation Markers by Simultaneous Measurement of Sense and Antisense DNA Strands after Cytosine Conversion.
Jensen SØ; Øgaard N; Nielsen HJ; Bramsen JB; Andersen CL
Clin Chem; 2020 Jul; 66(7):925-933. PubMed ID: 32460325
[TBL] [Abstract][Full Text] [Related]
53. Walking pathways with positive feedback loops reveal DNA methylation biomarkers of colorectal cancer.
Kel A; Boyarskikh U; Stegmaier P; Leskov LS; Sokolov AV; Yevshin I; Mandrik N; Stelmashenko D; Koschmann J; Kel-Margoulis O; Krull M; Martínez-Cardús A; Moran S; Esteller M; Kolpakov F; Filipenko M; Wingender E
BMC Bioinformatics; 2019 Apr; 20(Suppl 4):119. PubMed ID: 30999858
[TBL] [Abstract][Full Text] [Related]
54. Detection of methylated septin 9 in tissue and plasma of colorectal patients with neoplasia and the relationship to the amount of circulating cell-free DNA.
Tóth K; Wasserkort R; Sipos F; Kalmár A; Wichmann B; Leiszter K; Valcz G; Juhász M; Miheller P; Patai ÁV; Tulassay Z; Molnár B
PLoS One; 2014; 9(12):e115415. PubMed ID: 25526039
[TBL] [Abstract][Full Text] [Related]
55. DNA methylation patterns in blood of patients with colorectal cancer and adenomatous colorectal polyps.
Cassinotti E; Melson J; Liggett T; Melnikov A; Yi Q; Replogle C; Mobarhan S; Boni L; Segato S; Levenson V
Int J Cancer; 2012 Sep; 131(5):1153-7. PubMed ID: 22020530
[TBL] [Abstract][Full Text] [Related]
56. CAHM, a long non-coding RNA gene hypermethylated in colorectal neoplasia.
Pedersen SK; Mitchell SM; Graham LD; McEvoy A; Thomas ML; Baker RT; Ross JP; Xu ZZ; Ho T; LaPointe LC; Young GP; Molloy PL
Epigenetics; 2014 Aug; 9(8):1071-82. PubMed ID: 24799664
[TBL] [Abstract][Full Text] [Related]
57. Circulating tumor DNA is a prognostic marker of tumor recurrence in stage II and III colorectal cancer: multicentric, prospective cohort study (ALGECOLS).
Benhaim L; Bouché O; Normand C; Didelot A; Mulot C; Le Corre D; Garrigou S; Djadi-Prat J; Wang-Renault SF; Perez-Toralla K; Pekin D; Poulet G; Landi B; Taieb J; Selvy M; Emile JF; Lecomte T; Blons H; Chatellier G; Link DR; Taly V; Laurent-Puig P
Eur J Cancer; 2021 Dec; 159():24-33. PubMed ID: 34731746
[TBL] [Abstract][Full Text] [Related]
58. Colorectal cancer screening with blood-based biomarkers: cost-effectiveness of methylated septin 9 DNA versus current strategies.
Ladabaum U; Allen J; Wandell M; Ramsey S
Cancer Epidemiol Biomarkers Prev; 2013 Sep; 22(9):1567-76. PubMed ID: 23796793
[TBL] [Abstract][Full Text] [Related]
59. The Diagnostic and Prognostic Significance of Serum Neutrophil Gelatinase-Associated Lipocalin Levels in Patients with Colorectal Cancer.
Ozemir IA; Aslan S; Eren T; Bayraktar B; Bilgic C; Isbilen B; Yalman H; Yigitbasi R; Alimoglu O;
Chirurgia (Bucur); 2016; 111(5):414-421. PubMed ID: 27819647
[TBL] [Abstract][Full Text] [Related]
60. Plasma clearance of RAS mutation under therapeutic pressure is a rare event in metastatic colorectal cancer.
Moati E; Blons H; Taly V; Garlan F; Wang-Renault SF; Pietrasz D; Didelot A; Garrigou S; Saint A; Pernot S; Taieb J; Laurent-Puig P; Zaanan A
Int J Cancer; 2020 Aug; 147(4):1185-1189. PubMed ID: 31472013
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
